{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031669","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.906012+00:00","generated_at":"2026-06-08T04:47:33.922276+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DiaMedica amends ReMEDy2 stroke trial protocol; cash $56.2M with runway to 2026","bullets":["FDA 30-day review of protocol amendments passed without comment; changes focus on moderate anterior circulation strokes (NIHSS 5-15).","Initial US clinical site activations expected in Nov-Dec 2023; full enrollment for interim analysis targeted by 2024.","Cash and investments $56.2M as of Sep 30, 2023, up from $33.5M at Dec 31, 2022; cash runway into 2026.","Q3 2023 R&D expenses $3.3M (vs $1.6M Q3 2022); G&A $1.9M (vs $1.5M); net cash used in operations $14.9M for nine months (vs $8.7M prior)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031669","json":"https://secwatch.observer/filing/0001437749-23-031669.json","markdown":"https://secwatch.observer/filing/0001437749-23-031669.md","text":"https://secwatch.observer/filing/0001437749-23-031669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/0001437749-23-031669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/dmtp20231112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:47:33.922276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0aac19b60e40667b07612739ef6238e85d9f8c4","claim":"DiaMedica Therapeutics Inc. reported financial results for three and nine-month periods ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three and nine-month periods ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of Item 2.02 of this report.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/0001437749-23-031669-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine-month periods ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}